Open access publishing of medical research is increasingly prevalent, but open access terminology is varied and confusing. Gold, green, bronze, hybrid, CC BY, CC BY-NC – what does it all mean, and what is the best type of open access? At the 14th Annual Meeting of the International Society of Medical Publication Professionals, a panel of stakeholders in medical publications met to discuss open access from different perspectives.
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
Here’s our summary of key points from selected presentations at the 2018 European meeting of ISMPP.
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.
Featuring the whodunit on the demise of Beall’s list, The Royal Society’s ORCID mandate and how authors and reviewers have responded to PeerJ’s optional open peer review. Who killed Beall's list? via The Chronicle of Higher Education A review of the prime suspects in the demise of Beall’s list, and a discussion on where open … Continue reading Weekly digest: the latest news on topics important to Open Pharma
Summary report from the Open Pharma workstream meetings in July
Open access publishing is on the rise, providing both opportunities and challenges for publishers, academics, funding bodies and pharma. However, academic authors collaborating with pharma prefer to publish in journals with the highest impact factor possible, and open access is not necessarily the authors’ priority. In our Open Pharma workstreams, we have identified a strong … Continue reading Open access education: time for a new approach?
Since the launch of Open Pharma in January 2017, groups of stakeholders have convened on a monthly basis to explore how to implement positive changes in scientific publishing across four key areas: open access; ORCID, CRediT and Convey; preprints and post-publication peer review; and layered publication platforms. The collated key insights and next steps from … Continue reading Update on Open Pharma workstreams: June 2017
The first Open Pharma workstream meetings took place last week. The collated key insights and next steps can be found below. If you would like to get involved, please refer to our contacts page. Workstream 1: Open access Key insights Next steps Before driving change, we need to define what we mean by open access Define … Continue reading Overview: Open Pharma workstream kick-off meetings
Questions from delegates at ISMPP US 2017 guided poster tour highlight practical issues presenting barriers to uptake of innovative platforms